Avion Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Avion Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16	Closed	–	–	1262
2025 Q2	$0	Buy	+16	New	+$494	﹤0.01%	1251

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Avion Wealth's CRNX Position: Q3 2025 in Review

Avion Wealth sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 16 shares.

Avion Wealth first reported a position in CRNX in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Avion Wealth reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Avion Wealth sold 16 Crinetics Pharmaceuticals shares in Q3 2025.
Avion Wealth first reported a position in Crinetics Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Avion Wealth's Crinetics Pharmaceuticals position peaked at $0 in Q2 2025.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Avion Wealth's 13F filing for Q3 2025, filed 24 Oct 2025.